Exact Sciences (EXAS)
(Real Time Quote from BATS)
$48.13 USD
+1.32 (2.82%)
Updated Jul 22, 2024 11:12 AM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXAS 48.13 +1.32(2.82%)
Will EXAS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAS
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Other News for EXAS
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
Exact Sciences (EXAS) Receives a Buy from Piper Sandler
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
November 15th Options Now Available For EXACT Sciences (EXAS)
Exact Sciences schedules second quarter 2024 earnings call